原位肝移植术后胆道狭窄的介入治疗

目的:探讨经T型管及其窦道和经皮肝穿刺胆道引流治疗原位肝移植术后胆道狭窄的可行性及其疗效.方法:对252例原位肝移植术后出现胆道狭窄的26例患者分别行胆道气囊扩张术、胆道引流术和胆道支架置入术.结果:3例胆道狭窄合并胆瘘患者和3例单纯吻合口狭窄患者,经气囊扩张术和胆道引流后痊愈.6例肝内外胆管多发狭窄患者,气囊反复扩张胆道狭窄段后,5例狭窄纠正而获得痊愈;1例气囊扩张治疗后出现肝内血肿,再次行肝移植.12例肝内外胆管多发狭窄合并胆泥的患者,经反复球囊导管扩张后,10例狭窄明显减轻,黄疸缓解;1例置入胆道支架,后因支架管阻塞而再次肝移植;1例治疗后狭窄仍存在,黄疸无缓解而再次肝移植.2例T型管引流口段狭窄行经皮肝穿刺胆道引流术后,狭窄明显减轻,黄疸缓解.结论:经T型管及其窦道和经皮肝穿刺胆道引流是治疗原位肝移植术后胆道狭窄的良好方法.     

肝移植术后胆管并发症的介入治疗

目的:评价介入方法治疗肝移植术后胆管并发症的价值。方法:对1999年10月~2005年6月53例肝移植患者术后发生胆道并发症的相关资料进行回顾性分析。结果:9例患者术后出现胆管并发症,使用经皮肝穿胆道引流(PTCD)治疗4例次,经内镜逆行胰胆管造影(ERCP)治疗5例次。手术均取得成功。患者的临床症状均有所好转。结论:介入方法治疗肝移植术后胆管并发症可获得较好的近期疗效,其远期结果有待于进一步观察。     

肝移植术后并发胆道狭窄的内镜下治疗

 目的:初步探讨内镜在肝移植术后胆道狭窄治疗中的临床应用价值.方法:通过十二指肠镜逆行胆管造影(endoscopic retrograde cholangiography,ERC)检查对肝移植术后胆道狭窄进行诊断,并根据检查结果做相应的内镜下介入治疗.结果:肝移植术后胆道狭窄38例,其中21例为吻合口狭窄(10例合并有胆瘘),17例为非吻合口胆道狭窄.针对不同情况进行鼻胆管引流术及塑料支架引流术等治疗,非吻合口胆道狭窄的患者内镜治疗较困难,需要多次进行内镜治疗.所有患者治疗后临床症状均明显改善,无严重并发症发生.结论:内镜对于肝移植术后胆道狭窄并发症的诊断与治疗安全而有效,胆道狭窄并发症的较快发现及时处理可使患者较快治愈.     

双引流管技术在四例肝移植术后胆道狭窄中的应用

目的 探讨双引流管技术在治疗肝移植术后胆道狭窄中的应用价值.方法 回顾性分析采用双引流管技术治疗4例肝移植术后胆道狭窄病例的资料.采用经皮经肝穿刺胆道引流介入技术,建立1～2条引流道置入双引流管.结果 4例胆道并发症均患者表现为肝内胆管和胆总管多发狭窄合并胆泥形成.患者平均年龄55岁,供肝冷缺血时间11.4 h、热缺...     

肝移植术后胆道并发症ERCP表现及内窥镜介入治疗

目的探讨肝移植术后胆道并发症的原因及影像学表现,并对部分并发症进行内窥镜介入治疗,以提高肝移植的成功率。方法通过十二指肠镜逆行胰胆管造影(ERCP)检查对肝移植术后胆道异常改变11例资料进行回顾性分析,并根据检查结果做相应的内窥镜下介入治疗。结果通过ERCP检查,对11例肝移植术后患者出现梗阻性黄疸原因得到明确诊断,其中,胆道胆泥形成2例,胆管吻合口狭窄6例,胆道腹腔漏3例。并对2例胆道胆泥进行了乳头括约肌切开(EST) 网蓝胆泥取出术;5例吻合口狭窄行气囊扩张或塑料内支架内引流(ERBD)及2例胆道腹腔漏行鼻胆管引流治疗(ENBD),治疗效果确切,经有针对性的预防和治疗后,除2例胆道腹腔漏分别于肝移植术后6月及11月病死和1例因胆管吻合口处完全阻塞未能放置内支架引流管,导致肝内胆汁淤积症并肝硬化及肝功能失代偿病死外,其余患者均痊愈出院,现仍长期存活,总生存率为72.7%。结论肝移植术后一旦怀疑胆道并发症时应及时行ERCP检查,并根据检查结果做内窥镜介入治疗。胆道并发症的及时发现和处理将可能使患者较快痊愈。     

肝移植术后血管胆道并发症的介入治疗

目的:评价介入治疗对肝移植后胆道、血管并发症的价值。材料和方法:18例肝移植患者接受了介入治疗。其中肝动脉狭窄8例,行肝动脉造影及溶栓治疗;下腔静脉及肝静脉狭窄2例,行内支架置入术;胆瘘及胆道狭窄8例,行PTCD治疗。结果:胆道并发症8例,PTCD治疗后症状消失;肝动脉狭窄8例,溶栓后肝动脉完全开放6例,1例血流部分开放,1例肝动脉血流未恢复再次肝移植治疗;下腔静脉及肝静脉狭窄2例内支架置入术后下腔静脉梗阻及肝肿大症状消失。结论:介入治疗是治疗肝移植后胆道血管并发症的有效方法。     

超声在肝移植术后胆道并发症诊治中的应用

目的:探讨超声在肝移植术后胆道并发症诊治中的价值.材料和方法: 6例实施肝移植术后临床拟诊胆道并发症的患者,以二维超声检查移植肝及肝周情况,以彩色多普勒超声评估肝动脉、下腔静脉血流,并与其他影像学检查相对比.结果: 胆系梗阻3例(2例合并肝内多发胆汁肿)、胆管内胆泥形成1例、胆漏2例(在超声引导下置管引流).肝动脉血栓2例.肝流出道狭窄合并血栓1例.结论: 超声在肝移植术道并发症的诊治中有着重要的应用价值.     

肝移植术后胆道并发症的影像学诊断

目的分析肝移植术后胆道并发症的影像学（ＣＴ、ＭＲＩ、“Ｔ”形管造影）表现。材料与方法回顾性分析了我院７例原位肝移植术后影像学资料,７例均为男性,年龄３３～５０岁,肝硬化病史４～１０年。术后１例行腹ＣＴ平扫,５例行平扫加增强扫描,１例行单纯增强扫描,其中３例作了ＭＲＩ检查。所有病例均行“Ｔ”形管造影。结果胆漏１例;肝内胆管狭窄１例,非吻合口胆总管狭窄１例。结论胆系造影是肝移植术后胆道系统并发症（胆漏、胆管狭窄）诊断的常规方法,ＣＴ及ＭＲＩ扫描可以显示间接征象。     

肝移植术后早期胆道并发症65例诊治体会

目的探讨肝移植术后早期胆道并发症的诊断和治疗。方法回顾性分析了我院2006年5月～2008年3月以来成功实施的65例肝移植的临床资料。其中尸肝移植54例，亲体肝移植11例，女性占16．92％（11／65），男性占83．08％（54／65）。结果本组65例肝移植患者其中有8例3个月内出现胆道早期并发症，发生率为12．31％（8／65），分别为胆漏3例，胆汁瘤1例，肝内胆汁湖1例，胆泥形成1例，胆道狭窄2例。女性患者早期胆道并发症发生率为9．09％（1／11），男性患者早期胆道并发症发生率为12．96％（7／54）。8例患者中，留置T管引流1例，未留置T管引流7例。治愈6例，好转2例，死亡0例（0％）。其中3例术后3d内出现单纯胆漏，通过留置的腹腔引流管得到及时的诊断，同时应用留置的腹腔引流管持续引流4周～2月后得到治愈。5例经B超、MRCP、ERCP得到诊断；1例胆汁瘤和1例肝内胆汁湖通过B超引导下穿刺引流而得到治愈；1例胆泥形成通过ERCP进行胆道冲洗后好转出院；2例通过ERCP进行球囊扩张或者放置支架后好转出院。结论肝移植术后早期胆道并发症的诊断主要手段是留置的腹腔引流管、B超、MRCP、ERCP等：肝移植术中留置的腹腔引流管对于肝移植术后早期胆漏的治疗起着特殊的作用：B超引导下穿刺引流是治疗胆汁瘤、胆汁湖的重要手段；ERCP下胆道冲洗对胆泥形成非常有效．ERCP下球囊扩张或者放置胆道支架对胆道狭窄的治疗很有效。     

肝移植术后胆道狭窄经皮肝穿刺胆管造影的并发症及其预防

目的观察经皮肝穿刺胆道介入治疗原位肝移植术后胆道狭窄发生并发症的频次和类型。资料与方法对292例原位肝移植术后出现胆道狭窄的30例患者分别行胆道球囊扩张术、胆道引流术和胆道支架置入术,观察术中反应、术后临床经过、相关实验室检查、B超和复查胆道造影表现。结果 3例(10.0%)胆道狭窄合并胆瘘患者和3例(10.0%)单纯吻合口狭窄患者行气囊扩张术和胆道引流后痊愈。8例(26.7%)肝内外胆管多发狭窄患者气囊反复扩张胆道狭窄段后,7例狭窄纠正而获得痊愈。14例(46.7%)肝内外胆管多发狭窄合并胆泥患者中12例(40.0%)狭窄明显减轻,黄疸缓解;2例(6.7%)T形管引流口段狭窄行经皮肝穿刺胆道引流术后,狭窄明显减轻,黄疸缓解。30例患者(100.0%)术中均感疼痛,其中12例(40.0%)疼痛剧烈。2例(6.7%)术中发生出血,其中1例再次行肝移植。27例(90.0%)术后胆管仍再狭窄,需反复多次成形。2例(6.7%)治疗后狭窄持续存在而再次行肝移植,其中1例曾置入胆道支架,另1例直接行二次肝移植。结论疼痛、再狭窄是经皮肝穿刺胆道介入治疗肝移植术后胆道狭窄的常见并发症,术中预防大出血是降低风险的关键。     

Early biliary complications of laparoscopic cholecystectomy: evaluation on T2-weighted MR cholangiography in conjunction with mangafodipir trisodium-enhanced 3D T1-weighted MR cholangiography

OBJECTIVE: Our aim was to assess preliminary experience with combined conventional T2-weighted and mangafodipir trisodium (MnDPDP)-enhanced T1-weighted MR cholangiography in evaluating early biliary complications of laparoscopic cholecystectomy. SUBJECTS AND METHODS: Conventional heavily T2-weighted MR cholangiography with MnDPDP-enhanced T1-weighted MR cholangiography and ERCP were performed in seven patients with high clinical suspicion of biliary complications after laparoscopic cholecystectomy. The final diagnoses of complications were classified according to the presence and degree of bile duct injury, bile leakage, and retained stones. RESULTS: The diagnoses on MR cholangiography were as follows: complete transection and occlusion of the common bile duct with bile leakage (n = 3), partial strictures of the common bile duct with bile leakage (n = 1), cystic duct leakage (n = 1), partial ligation of an aberrant right hepatic duct (n = 1), and hemorrhage without biliary complication (n = 1). The final diagnoses at surgery (n = 2) and ERCP (n = 5) were as follows: complete transection and occlusion of the common bile duct with bile leakage (n = 2), partial strictures of the common bile duct with bile leakage (n = 2), cystic duct leakage (n = 1), partial ligation of an aberrant right hepatic duct (n = 1), and hemorrhage without biliary complication (n = 1). MR cholangiography accurately yielded the same findings as the final diagnoses, except in one case with partial stricture of the bile duct with bile leakage (overdiagnosed as complete occlusion on MR cholangiography). CONCLUSION: Combined conventional T2-weighted and MnDPDP-enhanced T1-weighted MR cholangiography may eliminate the use of other studies for the imaging of biliary complications after cholecystectomy if this preliminary data can be verified in a larger study.     

Biliary leaks: treatment by means of percutaneous transhepatic biliary drainage

PURPOSE: To evaluate the efficacy of percutaneous transhepatic biliary drainage in the treatment of biliary leaks. MATERIALS AND METHODS: Sixteen patients with a biliary leak involving either the common bile duct (n = 12), the biliary confluence (n = 2), or a hepaticojejunal anastomosis (n = 2) were treated by means of percutaneous transhepatic biliary drainage. The biliary leak was due to severe acute necrotizing pancreatitis in six patients, while 10 patients had postoperative leak. Percutaneous transhepatic biliary drainage was performed with a 12-F catheter, with two series of side holes positioned on both sides of the extravasation to divert bile flow away from the defect. RESULTS: In 13 patients, the biliary leak healed after drainage (mean duration, 78 days). In four of these patients, a slight residual narrowing of the bile duct was treated by means of either balloon dilation (n = 2) or balloon dilation followed by insertion of a metallic stent (n = 2). All 13 patients remained cured (mean follow-up, 38 months). Two patients with severe acute necrotizing pancreatitis died of complications unrelated to the biliary leak. Vascular complications occurred in two patients, one of whom died after surgical drainage of a subcapsular hematoma. CONCLUSION: Biliary leaks can be treated successfully by means of percutaneous transhepatic biliary drainage. The procedure is particularly useful when surgical or endoscopic management has failed.     

恶性梗阻性黄疸介入治疗并发症分析及其防治的探讨

目的探讨经皮经肝胆管引流和置入内支架治疗恶性梗阻性黄疸的方法及并发症的预防。方法65例恶性梗阻性黄疸患者接受经皮经肝胆管引流和置入内支架治疗。其中肝门部肝癌18例,胆管癌16例,胆囊癌累及胆总管3例,胃癌肝门淋巴结转移16例,胰腺癌8例,胆肠吻合术后吻合口狭窄4例。结果20例放置了胆管支架,其中2例因左右肝总管梗阻各放置了2枚金属内支架;15例放置了内外引流管;29例单纯放置外引流管;1例右侧胆管放置支架,左侧放置内外引流管。与操作有关的并发症为胆管出血2例,其中胆管出血致出血性休克1例;感染4例,2例出现败血症;肝功能损害5例;局限胆汁性腹膜炎并发反应性胸腔积液1例;电解质紊乱1例;引流管部分移位或脱出8例;引流管阻塞2例;支架置入后早期发生再狭窄1例。结论恶性梗阻性黄疸介入治疗方法简单、疗效确切,正确选择适应证、规范操作技术可以减少并发症的发生。     

Bile duct: analysis of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction

PURPOSE: To evaluate percutaneous transluminal forceps biopsy in patients suspected of having a malignant biliary obstruction. MATERIALS AND METHODS: One hundred thirty consecutive patients (82 men and 48 women; mean age, 59 years) with obstructive jaundice underwent transluminal forceps biopsy during or after percutaneous transhepatic biliary drainage. The lesions involved the common bile duct (n = 58), common hepatic duct (n = 39), hilum (n = 14), ampullary segment of the common bile duct (n = 11), right or left intrahepatic bile duct (n = 5), or the entire extrahepatic bile duct (n = 3). In each patient, three to five specimens (mean, 4.1 specimens) were taken from the lesion with 5.4-F biopsy forceps. The final diagnosis for each patient was confirmed with pathologic findings at surgery, additional histocytologic data, or clinical and radiologic follow-up. Statistical analysis was performed with the chi(2) test; a P value < or =.05 was considered to indicate a significant difference. RESULTS: Ninety-eight of 130 biopsies resulted in correct diagnoses of malignancy. Five biopsy diagnoses proved to be true-negative. There were 27 false-negative diagnoses and no false-positive diagnoses. The diagnostic performance of transluminal forceps biopsy in malignant biliary obstructions was as follows: sensitivity, 78.4%; specificity, 100%; and accuracy, 79.2%. Sensitivity of biopsy in the 82 patients with cholangiocarcinoma was higher than in the 43 patients with malignant tumors other than cholangiocarcinoma (86.6% vs 62.8%, P <.005). Sensitivity was significantly lower in the ampullary segment of the common bile duct than in other sites (P <.01). No major complications related to the biopsy procedures occurred. CONCLUSION: Percutaneous transluminal forceps biopsy is a safe procedure that is easy to perform through a transhepatic biliary drainage tract. It provides relatively high accuracy in the diagnosis of malignant biliary obstructions.     

Value of MRCP with Mangafodipir Trisodium (Teslascan) injection in the diagnosis and management of bile leaks

PURPOSE: To assess the value of MRCP with Mangafodipir Trisodium (Teslascan) injection in the diagnosis and management of bile leaks. PATIENTS AND METHODS: Retrospective study of 25 patients (18 males, 7 females) with a mean age of 49.7 years and high clinical suspicion of bile leak who underwent MRCP with Mangafodipir Trisodium (Teslascan) injection between 2002 and 2006. The suspected etiology for bile leak was surgical (n=17), traumatic (n=7) or medical (n=1). The clinical suspicion was based on a combination of clinical, laboratory and imaging findings. RESULTS: MRCP with Teslascan injection demonstrated a bile leak in 20 patients. The site of leak was depicted in 17 cases: second order of smaller bile duct, (n=9), hepatic duct (n=3), confluence (n=2), cystic duct (n=1), bilioenteric anastomosis (n=2). Management based on MR findings included biloma drainage (n=7), biliary drainage (n=5), endoscopic management (n=2), repeat surgery (n=3), expectant management (n=1), and medical management (n=1). Outcome was favourable in 18 cases. Two patients died from infectious complications. CONCLUSION: In addition to confirming a diagnosis of bile leak, MRCP with Teslascan injection depicts the site of leak allowing optimal management.     

介入治疗T管引流术后胆道再狭窄的初步探讨

目的 评价介入治疗外科T管引流后胆道再狭窄的疗效、安全性、可行性.方法 回顾性分析2014年6月-2016年3月收治的T管术后胆道再狭窄的25例患者资料,其中胆管癌6例,胆囊癌3例,胆系结石13例,肝癌2例,胃癌外科术后1例.25例中合并胰胆管合流异常4例.经原T管途径行介入治疗22例,经T管造影后再行PTCD治疗3例.所有患者中,行球囊扩张配合胆道引流者21例,行胆道金属支架植入者4例.良性狭窄患者引流管保留2～3个月后给予拔除.患者经门诊或电话随访3～24个月,通过引流管造影评价疗效.结果 介入手术均顺利,无相关并发症发生,技术成功率100％.15例良性胆道狭窄患者经原T管窦道途径行球囊扩张成形术,留置胆道10.2～12 F内外引流管,拔除原T管.随访发现1例胆管癌吻合口狭窄患者术后8个月死于肺部感染.10例恶性狭窄中,3例胆道梗阻位于T管上方,均行PTCD术;其中2例肝癌侵犯胆道患者,癌栓范围较大,行内外引流管植入;黄疸消退后分别于术后1个月、2.2个月死于肝衰竭;1例胆囊癌侵犯胆道行支架植入,术后2.5个月死于肿瘤进展.7例胆道梗阻位于T管下方,经T管窦道途径植入内外引流管4例,植入金属支架3例.其中2例胆囊癌患者分别于术后3.8个月、5个月死于肿瘤进展;5例胆管癌患者中2例术后3个月出现支架再狭窄,给予PTCD处理.3例于术后3.6个月、5.2个月、9个月死于肿瘤进展、多脏器功能衰竭.结论 介入治疗外科T管引流后胆道再狭窄疗效确切,安全可行,可明显改善患者生活质量.     

Mangafodipir trisodium-enhanced magnetic resonance cholangiography for detection of bile leaks

PURPOSE: To assess the value of contrast-enhanced magnetic resonance cholangiography with Teslascan perfusion for the detection and localization of trauma-induced and postoperative bile leaks. MATERIALS AND METHODS: Between October 2002 and December 2004, 7 patients with suspected bile duct leaks after trauma (n = 2) or surgery (n = 5) requiring morphological evaluation were included. MRI examination included single shot fast spin- echo T2 weighted and gradient echo T1 weighted images prior to and 112 minutes in average after IV administration of mangafodipir trisodium. The results of contrast enhanced MR cholangiography were correlated to surgery (n = 3), clinical course (n = 3) and percutaneous drainage (n = 1). RESULTS: Mangafodipir trisodium-enhanced imaging showed extravasated Teslascan in collections in 6 patients (86%) whereas the combination of T2 weighted images and mangafodipir trisodium enhanced images revealed biliary collections in 7 patients (100%). The fistula between bile duct and collection was visualized in 4 patients (57%) before mangafodipir trisodium perfusion and in 3 patients (43%) after injection. In one patient the fistula was visible only after injection. Combination of both pre- and post injection MR correctly depicted the origin of bile leak in 5 cases (71%). CONCLUSION: Mangafodipir trisodium-enhanced magnetic resonance cholangiography is a non invasive technique that can successfully detect the presence of bile duct leaks. The combination of T2 weighted MR cholangiography and mangafodipir trisodium-enhanced T1 weighted MR cholangiography increases the sensitivity in detection and localization of the site of bile leak.     

经导管肝动脉化疗栓塞术后胆管损伤的临床意义

目的 观察经导管肝动脉化疗栓塞术（TACE）治疗肝脏恶性肿瘤后继发胆管损伤的发生率、影响因素和临床过程.方法 对1240例患者做TACE 2 680次,术前影像学检查均无明确胆系异常表现,18例于术后3周～3个月出现胆管损伤并发症.采用回顾性调查,观察TACE术后胆管损伤的发生率、临床表现、转归以及影响因素.结果肝转移性肿瘤TACE后胆管损伤的发生率为8.8%（13/148）,肝细胞性肝癌（HCC）组为0.5%（5/1092）.胆管损伤的影像学表现有局灶性胆管扩张4例、多发性肝内胆管扩张8例、囊性病灶或胆汁瘤6例.3例多灶胆管损伤表现为轻度黄疸,2例对保守治疗反应良好,1例于出现黄疸后2周死于肝功能衰竭.4例胆汁瘤合并感染,3例采取经皮穿刺置管引流和抗生素治疗,其中2例死于感染囊腔破入腹腔、继发化脓性腹膜炎,1例治愈;1例仅用抗生素治愈.与胆管损有关的病死率为16.7%（3/18）.其余11例无相关症状.统计学分析显示：无肝硬变背景的肝转移瘤患者TACE术后胆管损伤发生率明显高于有肝硬变的HCC患者（P〈0.01）;其他高危因素有肿瘤为少血供型（P〈0.01）和用铂类制剂与碘油乳化后做超选择性栓塞（P〈0.01）.结论 认识TACE后继发胆管损伤的影像学表现可避免误诊,特别是肿瘤复发.对存在胆管损伤高危因素患者,适当减少碘油乳化的化疗剂（特别是铂类）剂量,有可能降低胆系缺血损伤并发症.     

Malignant biliary obstruction: treatment with ePTFE-FEP- covered endoprostheses initial technical and clinical experiences in a multicenter trial

PURPOSE: To determine and present the initial technical and clinical results of using an expanded polytetrafluoroethylene-fluorinated ethylene propylene (ePTFE-FEP)-covered biliary endoprosthesis to treat malignant biliary obstruction. MATERIALS AND METHODS: This prospective nonrandomized study included 42 patients with malignant obstruction of the common bile duct, common hepatic duct, and hilar confluence. Unilateral (n = 38) or bilateral (n = 4) bile duct drainage was performed by using fully covered endoprostheses with anchoring fins. To avoid branch duct blockage, endoprostheses with drainage holes at the proximal end were available. Procedure- and device-related complications were recorded. Patient survival and stent patency rates were calculated with Kaplan-Meier survival analysis. Mean follow-up bilirubin and alkaline phosphatase levels were calculated, and differences in means were evaluated with a paired t test. RESULTS: Successful deployment, correct positioning, and patency of the device were achieved in all patients. Procedure-related complications occurred in two (5%) patients. Thirty-day mortality rate was 20% (eight of 41 patients), and median survival time was 146 days. Laboratory values decreased significantly after the procedure (P <.001). Recurrent obstructive jaundice occurred in six (15%) patients. Primary patency rates at 3, 6, and 12 months were 90%, 76%, and 76%, respectively. Calculation of the composite end point of death or obstruction revealed a median patency duration of 138 days. No endoprosthesis migration was observed. Branch duct obstruction was observed in four (10%) patients. Postmortem examination of one stent revealed a widely patent endoprosthesis with intact covering. CONCLUSION: Initial results of percutaneous treatment of malignant biliary obstructions with fully covered ePTFE-FEP endoprostheses suggest that they are safe and potentially clinically effective.